Accuray Incorporated logo

Accuray Incorporated

ARAY

NASDAQHealthcareMedical - Devices

Previous close

$0.281

−$0.0114 · -3.90%

Aug 21, 4:00 PM ET

Pre-market

$0.2808

−$0.0002 · -0.07%

Aug 24, 6:38 AM ET

ARAY company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

70

Undervalued

Momentum

17

Strong Down

Sentiment

46

Mixed

Risk resilience

25

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Stephen R. LaNeve
Listed since
Feb 8, 2007
Employees
990

Market position

Day range

Current $0.281

52-week range

Current $0.281

Open
$0.2928
Previous close
$0.2924
Volume
466.71K
0.17× average
Average volume
2.75M
Average daily volume
Market cap
33.43M USD
Beta
1.39
Market reference 1
50-day average
$0.2808
+0.07% above average
200-day average
$0.558
-49.64% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
174.26M USD
EV / EBITDA
-12.15×
Earnings yield
-155.60%
Free cash flow yield
0.00%

Profitability & efficiency

Return on equity
-117.97%
Return on assets
-11.09%
Return on invested capital
-10.09%

Financial health

Current ratio
1.5×
Altman Z-score
-0.68
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends42%22%3%-17%Gross margin, FY2022: 37.21%Gross margin, FY2023: 34.40%Gross margin, FY2024: 32.01%Gross margin, FY2025: 32.05%Gross margin, FY2026: 27.73%Operating margin, FY2022: 1.90%Operating margin, FY2023: 0.53%Operating margin, FY2024: 0.11%Operating margin, FY2025: 1.71%Operating margin, FY2026: -6.58%Net margin, FY2022: -1.24%Net margin, FY2023: -2.07%Net margin, FY2024: -3.48%Net margin, FY2025: -0.35%Net margin, FY2026: -12.24%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 37.21%. Gross margin FY2023 34.40%. Gross margin FY2024 32.01%. Gross margin FY2025 32.05%. Gross margin FY2026 27.73%. Operating margin FY2022 1.90%. Operating margin FY2023 0.53%. Operating margin FY2024 0.11%. Operating margin FY2025 1.71%. Operating margin FY2026 -6.58%. Net margin FY2022 -1.24%. Net margin FY2023 -2.07%. Net margin FY2024 -3.48%. Net margin FY2025 -0.35%. Net margin FY2026 -12.24%.

Income trends

Revenue

401.95M USD-12.34%

Operating income

−26.44M USD−34.28M USD

Net income

−49.19M USD-2992.02%
Income trends across reported periods509.27M USD306.2M USD103.12M USD−99.96M USDRevenue, FY2022: 429.91M USDRevenue, FY2023: 447.61M USDRevenue, FY2024: 446.55M USDRevenue, FY2025: 458.51M USDRevenue, FY2026: 401.95M USDOperating income, FY2022: 8.15M USDOperating income, FY2023: 2.38M USDOperating income, FY2024: 504K USDOperating income, FY2025: 7.84M USDOperating income, FY2026: −26.44M USDNet income, FY2022: −5.35M USDNet income, FY2023: −9.28M USDNet income, FY2024: −15.55M USDNet income, FY2025: −1.59M USDNet income, FY2026: −49.19M USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 429.91M USD. Revenue FY2023 447.61M USD. Revenue FY2024 446.55M USD. Revenue FY2025 458.51M USD. Revenue FY2026 401.95M USD. Operating income FY2022 8.15M USD. Operating income FY2023 2.38M USD. Operating income FY2024 504K USD. Operating income FY2025 7.84M USD. Operating income FY2026 −26.44M USD. Net income FY2022 −5.35M USD. Net income FY2023 −9.28M USD. Net income FY2024 −15.55M USD. Net income FY2025 −1.59M USD. Net income FY2026 −49.19M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue401.95M USD458.51M USD446.55M USD447.61M USD429.91M USD
Cost of goods sold290.49M USD311.54M USD303.63M USD293.65M USD269.95M USD
Gross profit111.45M USD146.97M USD142.92M USD153.96M USD159.96M USD
Research and development37.75M USD47.94M USD49.73M USD57.13M USD57.75M USD
Selling, general, and administrative83.97M USD91.19M USD92.69M USD94.45M USD94.06M USD
Operating expenses137.9M USD139.13M USD142.42M USD151.58M USD151.81M USD
Interest income1.19M USD
Interest expense35.31M USD12.95M USD11.62M USD10.63M USD8.13M USD
Depreciation and amortization6.15M USD5.91M USD4.53M USD5.51M USD
Operating income−26.44M USD7.84M USD504K USD2.38M USD8.15M USD
Net income−49.19M USD−1.59M USD−15.55M USD−9.28M USD−5.35M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-173.36%
11 comparable reports
Latest EPS result
-0.02
Estimate -0.03 · Beat by 33.33%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.07-0.03-0.12-0.22Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 0.02, estimate -0.01, surprise +300.00%, Beat. Q2 2025, reported Apr 30, 2025: actual -0.01, estimate -0.05, surprise +80.00%, Beat. Q3 2025, reported Aug 13, 2025: actual 0.01, estimate 0.03, surprise -65.63%, Miss. Q4 2025, reported Nov 5, 2025: actual -0.18, estimate -0.01, surprise -1700.00%, Miss. Q1 2026, reported Feb 4, 2026: actual -0.11, estimate -0.108, surprise -2.23%, Miss. Q2 2026, reported May 6, 2026: actual -0.09, estimate -0.05, surprise -80.00%, Miss. Q3 2026, reported Aug 19, 2026: actual -0.02, estimate -0.03, surprise +33.33%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.07, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates132.64M117.71M102.78M87.85MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 116.17M USD, estimate 110.36M USD, surprise +5.27%, Beat. Q2 2025, reported Apr 30, 2025: actual 113.24M USD, estimate 123.78M USD, surprise -8.51%, Miss. Q3 2025, reported Aug 13, 2025: actual 127.54M USD, estimate 92.95M USD, surprise +37.22%, Beat. Q4 2025, reported Nov 5, 2025: actual 93.94M USD, estimate 122.9M USD, surprise -23.56%, Miss. Q1 2026, reported Feb 4, 2026: actual 102.24M USD, estimate 100.86M USD, surprise +1.37%, Beat. Q2 2026, reported May 6, 2026: actual 104.85M USD, estimate 111.9M USD, surprise -6.30%, Miss. Q3 2026, reported Aug 19, 2026: actual 100.92M USD, estimate 105.3M USD, surprise -4.16%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate 95.8M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

13 ratings
Strong buy00%
Buy862%
Hold431%
Sell18%
Strong sell00%

ARAY peers

ETFs holding ARAY

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ARAY

research.disclaimer